On December 5, 2019, the United States Food and Drug Administration (FDA) announced that they had approved the applications from three separate pharmaceutical companies for the first generic versions of Gilenya® (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.
Read News ArticleSearch Results for:
What’s New in MS Research: November 2019
This edition of MSAA’s “What’s New in MS Research” provides highlights from this year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Experts from throughout the world gathered in Stockholm, Sweden in mid-September to share and discuss the latest research into the causes, diagnosis, course, and treatment of multiple sclerosis.
Read News ArticleMSAA’s Magazine, The Motivator, Wins a 2019 National Health Information Award
The Multiple Sclerosis Association of America (MSAA) is pleased to announce that we have received an award from the 26th Annual National Health Information Awards! Each year, the National Health […]
Read News ArticleVumerity™ Oral Capsules Approved by the FDA for Adults with Relapsing Forms of MS, Including Active SPMS
On October 30, 2019, Biogen Inc. and Alkermes plc announced the United States Food and Drug Administration (FDA) approval of Vumerity™ (diroximel fumarate) oral capsules to treat adults with relapsing forms of multiple sclerosis (MS). This approval includes the treatment of clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS).
Read News ArticleMS Research Mythbusting
Featuring Mitzi Joi Williams, MD While multiple sclerosis affects all races and ethnicities, minority populations may bear an unequal burden from the disease, including a higher risk of aggressive disease […]
Read News ArticleMultiple Sclerosis Association of America and Novartis Join Forces with TV Personality Montel Williams to Heighten Awareness of MS Progression through Storytelling
The Multiple Sclerosis Association of America (MSAA), in partnership with Novartis Pharmaceuticals Corporation and Emmy Award-winning television personality and multiple sclerosis (MS) advocate Montel Williams, announced today the launch of […]
Read News ArticleMSAA Partners with eSSENTIAL Accessibility
The Multiple Sclerosis Association of America (MSAA) is proud to announce a partnership with eSSENTIAL Accessibility, a comprehensive digital accessibility platform to assist in continuing MSAA’s commitment in providing informative […]
Read News ArticleMSAA’s 50th Anniversary
Founded in 1970, MSAA is marking its 50th anniversary in 2020 as a nonprofit organization dedicated to supporting the multiple sclerosis community and Improving Lives Today through vital services and […]
Read News ArticleClinical Trials: The Key to Progress in Treating Pediatric MS
In May 2018, Gilenya® (fingolimod) became the first drug approved by the United States Food and Drug Administration (FDA) to treat multiple sclerosis (MS) in pediatric patients.1 Thousands of researchers […]
Read News ArticleUp Front: Strategic Planning and Continued Development
Gina Ross Murdoch By Gina Ross Murdoch MSAA President and CEO With the arrival of autumn, I am reminded of how quickly the seasons pass by with so much activity […]
Read News Article